Current evidence positions GPNMB at the intersection of immunometabolism and stromal remodeling, with its RGD and PKD domains serving as actionable targets to disrupt tumor-immune crosstalk (Chung et al., 2007a; Chung et al., 2007b). Here, GPNMB is linked to neoplasm.